Literature DB >> 2427186

Treatment of retroperitoneal residual tumor after PVB chemotherapy of nonseminomatous testicular tumors.

W A Gelderman, H S Koops, D T Sleijfer, J W Oosterhuis, J Oldhoff.   

Abstract

Twenty-five patients with nonseminomatous testicular tumors stages IIB and IIC were treated at the Groningen University Hospital between January 1978 and April 1983. One patient died from his extensive tumor during chemotherapy. The remaining 24, treated by combination chemotherapy with cisplatin, vinblastine, and bleomycin as well as by surgery, are all alive after a mean follow-up period of 56 months. A laparotomy was performed after chemotherapy in each of the 24 cases. In four patients no residual tumor was found. Residual tumor was resected in 20 patients, in 13 the tumor contained only necrosis and fibrosis, 7 had mature teratoma. Comparison of the histologic features of the primary testicular tumor with those of the retroperitoneal residual tumor after chemotherapy, revealed that if the primary tumor did not contain a teratoma component the residual tumor showed only necrosis and/or fibrosis. When the primary tumor contained a teratoma component, mature teratoma was found in 50% (7/14) of the residual tumors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427186     DOI: 10.1002/1097-0142(19861001)58:7<1418::aid-cncr2820580706>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Chromosomal damage in peripheral blood lymphocytes of patients treated for testicular cancer.

Authors:  E van den Berg-de Ruiter; B de Jong; N H Mulder; G J te Meerman; H Schraffordt Koops; D T Sleijfer
Journal:  Hum Genet       Date:  1990-01       Impact factor: 4.132

2.  Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer.

Authors:  E W Steyerberg; H J Keizer; S D Fosså; D T Sleijfer; D F Bajorin; J P Donohue; J D Habbema
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

3.  Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours.

Authors:  M P Napier; A Naraghi; T J Christmas; G J Rustin
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

4.  A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumours.

Authors:  Ciara Conduit; Wei Hong; Felicity Martin; Benjamin Thomas; Nathan Lawrentschuk; Jeremy Goad; Peter Grimison; Nariman Ahmadi; Ben Tran; Jeremy Lewin
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

5.  External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients.

Authors:  Y Vergouwe; E W Steyerberg; R de Wit; J T Roberts; H J Keizer; L Collette; S P Stenning; J D F Habbema
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.